Currently, when glycosylated hemoglobin (HbA1c) is not well controlled, add‐on therapy with insulin is the next step for patients with type 2 diabetes (T2DM) who fail glycemic control with lifestyle intervention and non‐insulin agents, as recommended by most of the treatment guidelines.8, 9, 10, 11, 12. The gene discussed is INS; the disease is type 2 diabetes mellitus.